Research - Palo Alto, California, United States
Navire Pharma, a subsidiary of BridgeBio Pharma, and in collaboration with the Institute for Applied Cancer Science at MD Anderson, is developing inhibitors of SHP2 as targeted therapeutics for the treatment of multiple cancers. Founded in 2017 with the aim of harnessing advances in understanding of SHP2 signaling to create novel targeted oncology medications, Navire is led by a team of veteran biotechnology executives. Together with patients and physicians, the company aims to bring safe, effective treatments to market as quickly as possible.
Outlook
Google Tag Manager
Google Font API
Mobile Friendly
CloudFlare Hosting